Onvatilimab, designated as JNJ-61610588, represents a innovative clinical antibody aimed at {PD-1 | the PD-1 protein) and currently undergoing review for various {cancer | malignant growths) indications . This engineered IgG4 monoclonal antibody exhibits significant promise in inhibiting PD-1 interaction with its partners, thus releasing immune cel